BIOMARIN provides therapeutics to treat rare genetic diseases and has brought five products to market. In the past 10 years, BioMarin has had a revenue increase of over 1,200 percent, a total of more than a billion dollars. This success, the innovative therapies and the global success of its treatments made BioMarin an easy choice for BV’s Most Innovative Pharma Company (US) award. The most striking feature for the judging panel was the fact that most of BioMarin’s revenue comes from outside the US, where single-payer systems pay essentially the same price for therapies as is charged in the United States.
